Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/223 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME12192262
PMID: 12192262
LR: 20051117
CED: 20020822
DCO: 20030128
Autoren: Jubb RW
Titel: Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002.
Quelle: Current opinion in rheumatology; VOL: 14 (5); p. 597-602 /200209/
PM: Print
SU: IM
Sprache: English
CY: United States
JID: 9000851
ISSN: 1040-8711
CO: CORHES
Institution: University of Birmingham, Selly Oak Hospital, UK. Ronald.jubb@uhb.nhs.uk
DT: Journal Article; Review
RN: 45
Schlagwörter
CT: ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; ANTIRHEUMATIC AGENTS/administration & dosage; ANTIRHEUMATIC AGENTS/*therapeutic use; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS/adverse effects; HUMANS; HYPERTENSION/chemically induced; INJECTIONS, INTRA-ARTICULAR; ISOENZYMES/antagonists & inhibitors; MEMBRANE PROTEINS; OSTEOARTHRITIS/*drug therapy; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES
CTG: APPLIKATION, ORALE; ALTE MENSCHEN; ALTE MENSCHEN, 80 JAHRE UND ÄLTER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; ANTIRHEUMATIKA/Verabreichung & Dosierung; ANTIRHEUMATIKA/*therapeutische Anwendung; CYCLOOXYGENASE 2; CYCLOOXYGENASE-2-INHIBITOREN; CYCLOOXYGENASEINHIBITOREN/unerwünschte Nebenwirkungen; MENSCH; HYPERTONIE/chemisch hervorgerufen; INJEKTIONEN, INTRAARTIKULÄRE; ISOENZYME/Antagonisten & Inhibitoren; MEMBRANPROTEINE; OSTEOARTHROSE/*Arzneimitteltherapie; PROSTAGLANDIN-ENDOPEROXID-SYNTHASE
TE: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Membrane Proteins; Cyclooxygenase 2/E.C. 1.14.99.1; PTGS2 protein, human/E.C. 1.14.99.1; Prostaglandin-Endoperoxide Synthases/E.C. 1.14.99.1
CR: E.C. 1.14.99.1; E.C. 1.14.99.1; E.C. 1.14.99.1
AB: There have been considerable advances in the drug treatments used to treat osteoarthritis. The development of selective cyclo-oxygenase inhibitors (COX-II) and confirmation of their efficacy and gastrointestinal safety will reduce treatment morbidity in the elderly. Guidelines for safe and appropriate use of COX-II drugs are now available. The role of anti-inflammatory drugs in precipitating cardiorenal events has been highlighted but remains to be fully evaluated. Glucosamine, diacerein, and hyaluronan may all be disease-modifying drugs for osteoarthritis but confirmatory studies are still needed.
» Volltext »

» Fenster schließen »